Actavis wants out of China

Share this article:

Actavis wants out of China. Bloomberg reports that the generics drugmaker said the country's business climate is too difficult to continue to operate in. “It wasn't worth the aggravation, the frustration or the concern,” CEO Paul Bisaro told Bloomberg at the JP Morgan Healthcare conference.

Bisaro added: “If we are going to allocate capital, we're going to do so where we can get the most amount of return for the least amount of risk. And China is just too risky.”

Bloomberg notes that Actavis has not been among the companies slammed with accusations of corruption and that the country makes up a small portion of the firm's business.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.